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Abstract
Background: The manual Generation II (Gen II) ELISA method used to measure Anti-Müllerian Hormone (AMH)
from Beckman Coulter has recently been superseded by a fully automated AMH immunoassay. The aim of this
study was to evaluate the performance of the Access AMH assay and directly compare it to the modified Gen II
ELISA method. A secondary aim was to verify that the fertile age-related AMH range previously established using
the Gen II ELISA could be used to interpret results from the new automated Access assay.
Methods: The precision, stability, linearity, measurement range and detection limits were determined using
recombinant AMH and patient serum samples. Different diluents and their effects on AMH concentration were
compared. A correlation study was performed on patient samples to compare the Access AMH assay to the ELISA
method on the Access2 and DxI800 analysers. The fertile AMH range was verified by comparing the 10th, 50th and
90th percentile values from both methods obtained from 489 natural conception pregnant women.
Results: The Access AMH assay showed good performance across the measuring range for both intra-assay (CV
1.41–3.30 %) and inter-assay (CV 3.04–5.76 %) precision and acceptable sample stability. Dilution of the high
concentration samples with the recommended diluent resulted in a small but significant downward shift in values.
The assay was linear over the range of values recommended by the manufacturer, allowing for accurate reporting
within the reported range. The two assay types were highly correlated (R2 = 0.9822 and 0.9832 for Access2 and
DxI800, respectively), and the differences observed between the Access2 and DxI800 analysers were within
clinically acceptable ranges, indicating that the methods are interchangeable. Furthermore, we demonstrated
that results from the published reference range for the Gen II ELISA correlate with those from the automated
Access AMH assay.
Conclusion: Here, we verified the published performance of the Access AMH assay and showed excellent
correlation with the Gen II ELISA method. Moreover, we validated this correlation by confirming that the
results from a fertile AMH reference range established using the preceding Gen II ELISA are interchangeable
with the new automated Access AMH assay.
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Background
Anti-Müllerian hormone (AMH) is expressed by the
ovarian granulosa cells of the female ovary where it has
important autocrine and paracrine regulator functions in
follicle development. It is predominantly produced by
the pre-antral and small antral follicles, and production
then declines during the final maturation process and
luteal phase [1]. AMH acts as an inhibitor of further
follicle recruitment and inhibits the response of larger
follicles to follicle-stimulating hormone (FSH)-induced
growth and selection [2, 3].
The number of growing follicles and the resultant level
of AMH released into the circulation is proportionate to
the size of the primordial follicle stock [4, 5]. While
other tests for ovarian reserve such as basal FSH remain
valuable to fertility investigation particularly for patients
with reduced ovarian reserve [6, 7], the serum concen-
tration of AMH is gonadotropin independent, thus it re-
mains relatively constant throughout the menstrual cycle
[8, 9]. Consequently, AMH serum concentration has
emerged as a unique biological marker for the size of
the residual follicular pool that exhibits high correlation
with ovarian reserve [10]. This single blood test can add-
itionally assist in the prediction of ovarian response to
stimulation, aid in the diagnosis of polycystic ovary syn-
drome (PCOS) and predict premature ovarian failure,
among other uses [11–14].
A number of AMH immunoassays have been developed
in the past; however, a lack of standardisation and technical
issues between different methods has led to confusion in
the interpretation of results and scepticism of AMH test re-
liability [15–17]. We recently established an AMH refer-
ence range of fertile women using the widely-used modified
AMH Gen II enzyme-linked immunosorbent assay (ELISA)
from Beckman Coulter [18]. The antibodies used in the
Gen II assay have now been adopted in the first commercial
fully automated AMH assay systems from Roche Diagnos-
tics (Elecsys) and Beckman Coulter (Access) for both the
Access2 and DxI800 instruments [19, 20]. Studies have re-
vealed good correlations between the Gen II and Elecsys as-
says; however, a consensus on correlation between the Gen
II ELISA and the new Access AMH assay has not been
reached [21, 22].
In the present study, we assessed the accuracy and re-
producibility of the Access AMH assay from Beckman
Coulter and performed a correlation study with the pre-
vious Gen II ELISA method. Furthermore, we deter-
mined whether our published age reference range of
AMH values from fertile women could be used to inter-
pret results from the new AMH assay.
Methods
The Beckman Coulter Access AMH immunoassay was
assessed for use on both the Beckman Coulter Access2
and DxI800 analysers. Assay precision was evaluated for
both intra- and inter-run precision using AMH quality
control (QC) material consisting of human recombinant
AMH (Beckman Coulter) at three known concentra-
tions. Aliquots of samples were frozen and thawed once
prior to testing. Intra-assay performance of the Access
AMH assay was determined from 10 replicates of the
assay QC material during the same running cycle, and
inter-assay performance was determined by analysing
the first run of QC material each day for nine consecu-
tive days. The data was calculated as CV % (standard de-
viation/mean × 100).
Sample stability was assessed on patient sera and QC
material. For patient sera, blood was allowed to clot in
SST tubes (Becton Dickinson), and the serum was sepa-
rated by centrifugation according to the manufacturer’s
recommendations before being stored at -20 °C until fur-
ther analysis. Stability at 4 °C was determined by testing
a sample from one patient in triplicate for eight consecu-
tive days. Stability over freeze/thaw cycles was assessed by
testing a fresh sample on day one, then freezing the
sample at -20 °C and thawing prior to testing for seven
cycles. The data was calculated as % deviation of mean
(mean – expected mean/expected mean × 100).
Assay linearity was confirmed across the measuring
range by testing dilutions of calibrator material (re-
combinant human AMH; Beckman Coulter) and
patient sera. The S5 AMH calibrator was diluted out
in a series using Sample Diluent A. The patient sera
dilution series was performed using a mix of sera
from patients with known high and low (<0.3 pmol/
L) AMH concentrations to ensure that no matrix ef-
fect was present. Linearity was determined using the
Cusum test for linearity.
Assay detection limits were determined using doubling
dilutions of a patient serum sample with wash buffer
(Beckman Coulter). The Limit of Blank (LoB) was calcu-
lated as the mean of the blank plus 1.645 times the
standard deviation of the blank, while the Limit of De-
tection (LoD) was calculated as the LoB plus 1.645 times
the standard deviation of low-level samples using the
highest standard deviation value of the low-level samples
tested.
Dilutions of three patient sera samples (AMH concen-
trations 75, 115 and 140 pmol/L; samples 1, 2 and 3 re-
spectively) were tested in duplicate, comparing neat
values with 1:5 dilutions in low concentration patient
sera, the recommended diluent from Beckman Coulter
(Sample Diluent A), or wash buffer. Dilution testing
was also performed on patient sera of mid- and high-
range concentrations (77 and 177 pmol/L), comparing
neat values and samples diluted 1:5, 1:10 and 1:16 in
Sample Diluent A or patient sera of AMH concentra-
tion <0.1 pmol/L. A set of patient samples of AMH
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concentration >70 pmol/L (n = 27) were assayed neat
or diluted 1:5 in Sample Diluent A. The results were
analysed by a two tailed t-test.
The correlation between the new automated Access
AMH assay and the previous Beckman Coulter AMH
Gen II ELISA: revised protocol [23] was determined on
both the Access2 and DxI800 analysers. Sample AMH
concentrations were determined by single measurements
from 142 fresh patient serum samples by the Gen II
ELISA. Then, the samples were stored at -20 °C and
thawed once before measurement using the automated
Access AMH method for each analyser. A further correl-
ation of 46 samples stored at -20 °C was conducted
between two separate Access2 analysers. Regression
analysis was performed using Passing-Bablok and Bland-
Altman methods of comparison [24, 25].
The fertile AMH reference range was previously deter-
mined [18]. Briefly, a prospective observational study
was conducted on 492 pregnant women in their first
trimester, aged between 20 and 44 years, who had all
conceived spontaneously without the use of ovarian
stimulation drugs within 2–3 months of attempted con-
ception. Blood samples were taken and stored at -80 °C,
and their AMH concentration was determined using the
revised Gen II assay. To test for correlations between
the reference ranges determined using the ELISA with
the automated AMH assay, 489 of the original samples
stored at -80 °C were thawed and tested on the DxI800
analyser using the automated AMH assay. The results
were analysed to create an age-stratified collection of
patient reference ranges. Patients were broken down
into 5-year age brackets, and the 10th, 50th and
90th percentile AMH values of each bracket were
calculated. These values were plotted using the me-
dian age of the patients for each bracket to create a
polynomial curve for the limits of the AMH refer-
ence range.
Statistical calculations were carried out using Micro-
soft Excel 14.0 and SPSS Statistics 22.0 for the t-tests.
Comparison studies were performed using Medcalc
Version 15.11.4. All research was conducted in accord-
ance with the ethics guidelines approved by the Genea
Ethics Committee (EC00289) under approval GEC0028
with informed consent obtained from all participants.
Results
Precision
The Access assay showed good performance across the
measuring range for the Access AMH Assay on both the
Access2 and DxI800 instruments (Table 1). Intra-assay
and inter-assay precision ranged from CV 1.41- 3.30 %
and CV 3.04-5.76 %, respectively, and are within the
ranges reported by Beckman Coulter.
Sample stability
Human recombinant QC material and patient sera
stored at 4 °C were shown to be stable over this time
period (deviation from day 1 mean: -0.67–3.58 %). The
effect of up to five freeze/thaw cycles on sample stability
was also minimal (deviation from day 1 mean: -0.11–
3.80 %; Table 2).
Linearity
The automated Access assay was established to be re-
markably linear over the range of measurement values
specified by Beckman Coulter when using either human
recombinant AMH material or patient sera (Fig. 1a
and b). Linear regression analysis yielded R2 values
between 0.9947 and 0.9996 and slope values between
0.9881 and 1.0528. Furthermore, there was no sig-
nificant deviation from linearity using the Cusum
test for linearity under all tested conditions. Similar
results were obtained using a dilution series of pa-
tient sera diluted in Sample Diluent A (unpublished
observations). These data indicate that the linear re-
lationship is maintained under the required assay
conditions and thus allows for accurate reporting
within the reported range.
Assay limits
A dilution series of samples at the lower end of the
measuring range resulted in good linearity on both the
Access2 (R2 = 0.9995, slope = 0.9488) and DxI800 analy-
sers (R2 = 0.9932, slope = 0.9093) (Fig. 1c). The LoD was
Table 1 AMH intra- and inter-assay precision on Access2 and DxI800 analysers
Intra-assay precision Inter-assay precision
Mean, pmol/L SD, pmol/L CV, % Mean, pmol/L SD, pmol/L CV, %
Access2 Control 1 6.27 0.09 1.51 6.23 0.24 3.85
Control 2 31.78 0.45 1.41 31.69 0.96 3.04
Control 3 97.85 1.64 1.68 97.19 3.35 3.45
DxI800 Control 1 6.40 0.21 3.30 6.31 0.28 4.36
Control 2 33.36 0.68 2.04 32.49 1.87 5.76
Control 3 103.18 2.98 2.89 98.54 4.52 4.59
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Table 2 AMH stability under different storage conditions
Stored at 4 °C Freeze/thaw
Mean, pmol/L SD, pmol/L Deviation, % Mean, pmol/L SD, pmol/L Deviation, %
Day 1 5.96 0.16 0.00 Fresh 5.96 0.16 0.00
Day 2 5.83 0.09 −2.29 x1 5.96 0.08 −0.11
Day 3 5.77 0.03 −3.24 x2 5.87 0.04 −1.57
Day 4 5.92 0.04 −0.67 x3 5.91 0.14 −0.89
Day 5 5.75 0.18 −3.58 x4 5.74 0.09 −3.80
Day 6 6.09 0.05 2.07 x5 5.81 0.18 −2.63
Day 7 5.75 0.01 −3.52 x6 5.74 0.04 −3.75




Fig. 1 Linearity of the Access AMH assay on the Access2 and DxI800 analysers using a. calibrator material or b. patient sera. c. Linearity at the low
end of the concentration range using patient sera. Regression line (blue), 95 % confidence intervals (red). All results are shown in pmol/L
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calculated to be 0.1055 on the Access2 and 0.0994 on
the DxI800, while the LoB was calculated to be 0.0200
on the Access2 and 0.0352 on the DxI800. All deter-
mined assay limits were lower than the values desig-
nated by Beckman Coulter (LoD = 0.14 pmol/L, LoB =
0.07 pmol/L) and confirmed the high sensitivity of
this new assay.
Dilution testing
A comparison of neat AMH concentrations with those
obtained using three different dilution materials revealed
that samples diluted in patient sera of low concentration
showed the least deviation from the neat value, followed
by Sample Diluent A and wash buffer (Additional file 1:
Figure S1a). The dilution effect was further investigated
by performing 1:5, 1:10 and 1:16 dilutions (1:16 being
the recommended dilution factor from Beckman
Coulter) on samples from patients with mid-range and
high-range AMH concentrations and measuring AMH
using the automated Access assay (Table 3). Dilution in
low AMH concentration sera resulted in -2.56–5.21 %
deviation from the mean neat result, while dilution in
Sample Diluent A resulted in a deviation from the neat
value of -3.63–13.31 %. This finding was confirmed by
testing a cohort of patient samples of AMH concentra-
tion >70 pmol/L and comparing the neat results with
the diluted (1:5 in Sample Diluent A) results (Additional
file 1: Figure S1b). Overall, the results display a consist-
ent decrease of approximately 10 % upon sample dilu-
tion, which, while significant (t-test p < 0.0001), would
not be clinically relevant. These data suggest that there
is no need for dilution of samples that are >70 pmol/L,
as required for the previous Gen II ELISA; in fact, the
opposite effect occurs upon dilution, where sample con-
centrations are negatively biased.
Correlation studies between assays and analysers
The correlation of the new Access AMH assay with the
preceding revised AMH Gen II ELISA was determined
by a comparative study of 142 patient samples (Fig. 2a).
Passing-Bablok regression analysis comparing the Gen II
ELISA with the Access AMH assay run on the Access2
and DxI800 analysers resulted in R2 values of 0.9822 and
0.9832 and slope values of 1.0014 and 0.9231, respect-
ively. All regression curves showed no significant devi-
ation from linearity, indicating good correlation between
these methods. The Bland-Altman analyses indicate an
absence of bias across the analytical range for all
comparisons.
The same patient cohort was used to perform a correl-
ation study between the Access2 and DxI800 analysers
using the Access AMH assay (R2 = 0.9964, slope =
1.0758). A smaller cohort of 46 patient samples was used
to perform a comparison between two Access2 analysers
located in different geographical locations (R2 = 0.9820,
slope = 1.0317). Regression analysis and Bland-Altman
plots demonstrate high correlation across the measuring
range between the results obtained on the different in-
struments (Fig. 2b).
Correlation study of normal AMH reference ranges
A large study cohort of 489 pregnant patients who were
used previously to establish a fertile AMH reference
range using the Gen II ELISA were re-tested using the
Access AMH assay. The results from both assays were
analysed to create an age-stratified collection of patient
reference ranges by plotting the age group against the
values of the median, 10th, 50th and 90th percentiles
(Fig. 3). The results between the two methods were
highly correlated (average CV 6.7 %), and the same sig-
nificant curvilinear relationship between AMH and age
was confirmed using the new AMH test. As a result, we
conclude that the previously determined reference range
can be used to interpret data from either assay.
Discussion
AMH measurement is emerging as an extremely useful
tool in a number of areas of reproductive medicine.
However, technical issues with regards to stability and
lack of standardisation between past AMH assays have
Table 3 Comparison of different dilution methods using the Access AMH Assay
Dilution in patient sera Dilution in sample diluent A
Dilution Mean, pmol/L CV, % Deviation, % Mean, pmol/L CV, % Deviation, %
Sample 1 Neat 76.90 0.50 0.00 76.90 0.50 0.00
1:5 74.82 1.09 −2.71 68.90 1.73 −10.41
1:10 74.63 1.59 −2.96 66.28 2.74 −13.81
1:16 77.81 1.11 1.18 68.04 1.36 −11.52
Sample 2 Neat 170.64 1.83 0.00 170.64 1.83 0.00
1:5 177.69 1.10 4.13 164.44 1.24 −3.63
1:10 176.71 0.64 3.56 154.80 0.46 −9.28
1:16 179.53 3.55 5.21 153.65 3.07 −9.96
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led to uncertainty in AMH test reliability and result in-
terpretation [15, 26, 27]. The findings of the correlation
studies herein demonstrate agreement between the
results generated by the AMH Gen II ELISA and the
Access AMH Assay. Comparing the automated Access
and manual ELISA method using the Access2 analyser
showed near complete agreement, while results from the
DxI800 analyser showed a slight difference within ac-
ceptable clinical ranges. These findings indicate that the
past issues have been overcome when comparing the
new and previous Beckman Coulter methods.
In support of our results, van Helden and Weiskirchen
[22] demonstrated good correlations between the Gen II
ELISA and both the Access AMH assay and the new au-
tomated Elecsys system from Roche, both of which util-
ise the same monoclonal antibodies. The authors also
demonstrated an extremely tight correlation between the
Access and Elecsys assays, and these results were further
A
B
Fig. 2 a. Correlation between Access AMH and Gen II ELISAs on the Access2 and DxI800 instruments (n = 142). b. Correlation between results
from Access2 analysers in different locations (n = 46) and Access2 and DxI800 analysers (n = 142). Upper panels represent the Passing-Bablok
diagram with the regression line (blue) and the 95 % confidence interval (red). Lower panels represent the Bland-Altman plots with mean (blue)
and 95 % confidence intervals (red). All results are shown in pmol/L
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validated by Nelson et al. [21]. Interestingly, Nelson et
al. [21] report a 22 % decrease in expected values and
distinct systematic bias between the old and new Beck-
man Coulter AMH assays with increasing concentra-
tions. Different sample storage and handling conditions
may have contributed to this discordance. Hyldgaard et
al. [28] demonstrated a similar pattern of bias between
the Gen II and Elecsys methods and proposed that this
may be in part due to inter-laboratory bias with the Gen
II method. The Gen II ELISA is a manual method and
thus would be more prone to inter-operator bias and
variation from a number of sources within the assay
itself. Our ELISAs were performed by a single experi-
enced operator and we used a large sample size, which
may account for the close correlation observed by our
laboratory. Furthermore, we have shown that the
dilution of high concentration samples and the use of
different diluents can cause a shift in values, which may
explain the conflicting results with high concentration
samples.
Assessment of the Access AMH assay revealed excel-
lent linearity and good performance across the measur-
ing range for both intra-assay and inter-assay precision
as would be expected for an automated immunoassay.
This assay exhibited greatly increased sensitivity when
compared to previous manual methods and aligned with
literature from the manufacturer allowing for accurate
reporting to 0.1 pmol/L. We demonstrated high levels of
AMH immunoreactive stability under refrigerated and
freeze/thaw conditions, though the long-term effect of
storage under different conditions was not within the
scope of this study. The results of the dilution testing re-
vealed that AMH samples greater than 70 pmol/L do
not need to be diluted as was required with the previous
Gen II ELISA. In fact, our study revealed that dilution
caused a negative shift of approximately 10 %, indicating
care should be applied in the interpretation of results
from diluted samples. This shift would not, however,
have a significant effect on clinical outcome.
This is the first paper to report an established fertile
age-related AMH reference range that is compatible
with the automated Access AMH assay. Numerous stud-
ies have determined AMH reference ranges; however,
the majority of this research was conducted using infer-
tile or presumably fertile study groups and former
methods [15, 16, 29–33]. Bonifacio et al. [18] recently
published an AMH normogram using the revised Gen II
ELISA method on a large cohort of first trimester preg-
nant patients who had conceived by natural and unaided
means. AMH levels have been shown by a number of
studies to exhibit little variation within and between
menstrual cycles and to be stable from pre-pregnancy
through the first trimester of pregnancy [34–36]; there-
fore, the study group was considered as representative of
a fertile population. Here, we conducted a full study
comprised of the same cohort using the automated Ac-
cess AMH assay and the Gen II ELISA. A comparison of
the results between the two assays showed variation
within the performance limits of both analysis methods.
This study further validated the results of our method
Fig. 3 Correlation between automated AMH and Gen II ELISA normal female reference ranges. Individual results (blue points) and 10th, 50th and
90th percentile median values for 5-year age groups for Access AMH and Gen II ELISA methods (n = 489)
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comparison and confirmed that our fertile reference
range of AMH values can be applied to both the previ-
ous ELISA and the new automated assay from Beckman
Coulter.
Conclusions
The two most important influences on the acquisition of
reliable clinical information are the dependability of the
measurements and the interpretation of the results. This
study verified the published performance of the new au-
tomated Access AMH assay from Beckman Coulter
showing a measuring range adequate for most IVF appli-
cations and the ability to detect values consistently
across this range. The automated assay exhibited high
levels of stability and sensitivity and showed correlation
with the existing ELISA method and between analyser
platforms. Furthermore, an age-related reference range
of AMH values was established for patients not already
undergoing infertility assessment, allowing for accurate
extrapolation of data to tailor treatment and prognosis
prediction in the wider population. These findings are
an encouraging step towards the necessary establishment
of universal clinically relevant cut-off values and the
standardisation of AMH assay results.
Additional file
Additional file 1: Figure S1. a. Effect of different diluents on the
expected outcome of three patient samples. b. Effect of 1:5 dilution with
Sample Diluent A on patient AMH concentration compared to neat
values using the Access AMH assay. (PDF 25 kb)
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